Given the complexity of AD pathophysiology — and the growing consensus that amyloid buildup triggers tau spread at an early stage, with inflammation playing a critical role in toxicity of both — combination therapies are highly likely to be required in AD [63]. Here, MAPT is linked to Alzheimer disease.